ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 37404752

CAR-NK cell therapy for glioblastoma: what to do next?

Xiong Q and 3 others. Front Oncol, 2023. Cited by 24 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. CAR-NK cell therapy for glioblastoma: what to do next? Papers, record 37404752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37404752

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CAR-NK cell therapy for glioblastoma: what to do next?
PubMed
Journal
Front Oncol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
2.1
iCite
Revised in PubMed
2023-07-18
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xiong QQi
2Zhu JJiao
3Zhang YYong
4Deng HHongxin

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References167

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130,962,163Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.Mol Ther2019https://conductscience.org/library/papers/30962163PubMed
217,536,308HER-2/neu expression in glioblastoma multiforme.Appl Immunohistochem Mol Morphol2007https://conductscience.org/library/papers/17536308PubMed
325,197,555Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.J Immunother Cancer2014https://conductscience.org/library/papers/25197555PubMed
433,266,177Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy.Cancers (Basel)2020https://conductscience.org/library/papers/33266177PubMed
532,726,145Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.Expert Opin Biol Ther2020https://conductscience.org/library/papers/32726145PubMed
635,327,456Assessing the Future of Solid Tumor Immunotherapy.Biomedicines2022https://conductscience.org/library/papers/35327456PubMed
725,712,293HER2 expression status in diverse cancers: review of results from 37,992 patients.Cancer Metastasis Rev2015https://conductscience.org/library/papers/25712293PubMed
82,236,070Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.Proc Natl Acad Sci U S A1990https://conductscience.org/library/papers/2236070PubMed
915,870,068Characterization of the interaction between interleukin-13 and interleukin-13 receptors.J Biol Chem2005https://conductscience.org/library/papers/15870068PubMed
1029,497,427Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Front Immunol2018https://conductscience.org/library/papers/29497427PubMed

1 to 10 of 167

See all 167 references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
42,256,247Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy.Polym Sci Technol2025https://conductscience.org/library/papers/42256247PubMed
41,998,834Natural Product 4-Acetylantroquinonol B Enhances NK Cell-Mediated Immunity Against Glioblastoma.Cancer Med2026https://conductscience.org/library/papers/41998834PubMed
41,929,521Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.Front Immunol2026https://conductscience.org/library/papers/41929521PubMed
41,403,931Shaping the glioblastoma microenvironment to enhance CAR-NK immunotherapy.Front Immunol2025https://conductscience.org/library/papers/41403931PubMed
41,366,964Glioblastoma insights: Focus on crosstalk with the suppressive tumor microenvironment and advanced therapeutic strategies.Medicine (Baltimore)2025https://conductscience.org/library/papers/41366964PubMed
40,868,217Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines2025https://conductscience.org/library/papers/40868217PubMed
40,510,336Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells.Front Immunol2025https://conductscience.org/library/papers/40510336PubMed
40,375,039Tumor heterogeneity and resistance in glioblastoma: the role of stem cells.Apoptosis2025https://conductscience.org/library/papers/40375039PubMed
40,193,323Single-cell transcriptomics reveals immunosuppressive microenvironment and highlights tumor-promoting macrophage cells in Glioblastoma.PLoS One2025https://conductscience.org/library/papers/40193323PubMed
39,961,649Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.Immunotherapy2025https://conductscience.org/library/papers/39961649PubMed

1 to 10 of 18

See all 18 cited by

Genes50

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CARTPT9,607PubTator's text mininghttps://conductscience.org/library/genes/9607NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD22610,666PubTator's text mininghttps://conductscience.org/library/genes/10666NCBI Gene
CD24451,744PubTator's text mininghttps://conductscience.org/library/genes/51744NCBI Gene
CD247919PubTator's text mininghttps://conductscience.org/library/genes/919NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD27680,381PubTator's text mininghttps://conductscience.org/library/genes/80381NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD80941PubTator's text mininghttps://conductscience.org/library/genes/941NCBI Gene
CD86942PubTator's text mininghttps://conductscience.org/library/genes/942NCBI Gene

1 to 10 of 50

See all 50 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37404752

GET https://conductscience.org/api/papers/v1/37404752/references?page=2

API referenceFor AI assistants